The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
Age: 18 - 99 years
Gender: All
We've found 1 total result for "Neoplasm Residual".